Preclinical evaluation of no-carrier-added [131I]meta-iodobenzyl guanidine, for the treatment of tumours transfected with the noradrenaline transporter gene

Boyd, M., Ross, S., Owens, J., Hunter, D., Babich, J., Zalutsky, M., Hamilton, T., Bell, S. and Mairs, R. (2004) Preclinical evaluation of no-carrier-added [131I]meta-iodobenzyl guanidine, for the treatment of tumours transfected with the noradrenaline transporter gene. Letters in Drug Design and Discovery, 1, pp. 50-57.

Full text not currently available from Enlighten.

Abstract

Meta-[131I]iodobenzylguanidine ([131I]MIBG), used for neuroblastoma treatment, binds to the noradrenaline transporter (NAT). After NAT gene transfection, other tumour types might be treatable with [131I]MIBG. At 14 MBq, carrier-added [131I]MIBG (1110 MBq/mg) delayed tumour regrowth in NAT gene-transfected xenografts by 39-days, while no-carrier-added [131I]MIBG (>104 GBq/mg) cured 100% of tumours

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Mairs, Professor Robert and Boyd, Dr Marie
Authors: Boyd, M., Ross, S., Owens, J., Hunter, D., Babich, J., Zalutsky, M., Hamilton, T., Bell, S., and Mairs, R.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cancer Sciences
Journal Name:Letters in Drug Design and Discovery
ISSN:1570-1808

University Staff: Request a correction | Enlighten Editors: Update this record